vasomotor symptoms, menopause
Women's health · 2025–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| fezolinetant Treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in patients unsuitable for menopausal hormone therapy (MHT). | Mar 2025 | Not recommended | 5 individuals Endocrine Society of Australia · Inherited Cancers Australia · Breast Cancer Network Australia |
| fezolinetant Treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in patients unsuitable for menopausal hormone therapy (MHT) due to… | Nov 2025 | Recommended with restriction | 26 individuals TBC Bayer Australia |
Who spoke
Endocrine Society of Australia · Inherited Cancers Australia · Breast Cancer Network Australia · TBC Bayer Australia
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| fezolinetantFezolinetant for treating moderate to severe vasomotor symptoms associated with menopause | TA1143 | recommended | 2026-03 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.